Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 12, 2026, 2:45 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 37 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Intra Abdominal Infections Clear all
Completed Phase 3 Interventional Results available

Ceftazidime-Avibactam for the Treatment of Infections Due to Ceftazidime Resistant Pathogens

NCT01644643
View directory record Official record
Conditions
Complicated Urinary Tract Infection, Complicated Intra-abdominal Infection
Interventions
Ceftazidime - Avibactam ( CAZ-AVI), Best Available Therapy, Metronidazole
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 90 Years
Enrollment
345 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2014
U.S. locations
2
States / cities
Shreveport, Louisiana • Lima, Ohio
Source: ClinicalTrials.gov public record
Updated Sep 28, 2017 · Synced Sep 12, 2026, 2:45 PM EDT
Completed Phase 3 Interventional Results available

Moxifloxacin in Pediatric Subjects With Complicated Intra-abdominal Infection

NCT01069900
View directory record Official record
Conditions
Intraabdominal Infections
Interventions
Moxifloxacin (Avelox, BAY12-8039), Ertapenem, Amoxicillin/Clavulanate, Moxifloxacin placebo, Ertapenem placebo, Amoxicillin/Clavulanate placebo
Drug
Lead sponsor
Bayer
Industry
Eligibility
3 Months to 17 Years
Enrollment
458 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2015
U.S. locations
2
States / cities
San Diego, California • Springfield, Massachusetts
Source: ClinicalTrials.gov public record
Updated Mar 19, 2018 · Synced Sep 12, 2026, 2:45 PM EDT
Completed Phase 2 Interventional Results available

Safety and Efficacy Study to Compare IV CXA 101/Tazobactam and Metronidazole With Meropenem in Complicated Intraabdominal Infections

NCT01147640
View directory record Official record
Conditions
Complicated Intra-abdominal Infection
Interventions
CXA-101/ tazobactam and metronidazole, meropenem plus saline placebo
Drug
Lead sponsor
Cubist Pharmaceuticals LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
Industry
Eligibility
18 Years to 90 Years
Enrollment
122 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2011
U.S. locations
11
States / cities
Orange, California • Torrance, California • Aurora, Colorado + 8 more
Source: ClinicalTrials.gov public record
Updated Oct 24, 2018 · Synced Sep 12, 2026, 2:45 PM EDT
Completed Phase 2 Interventional

A Study to Assess the Safety, Tolerability, and Pharmacokinetics of Cefiderocol in Hospitalized Neonates and Infants

NCT06086626
View directory record Official record
Conditions
Gram-Negative Bacterial Infections
Interventions
Cefiderocol, Standard of Care
Drug
Lead sponsor
Shionogi
Industry
Eligibility
Up to 3 Months
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2025
U.S. locations
2
States / cities
Little Rock, Arkansas • Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Mar 1, 2026 · Synced Sep 12, 2026, 2:45 PM EDT
Completed Phase 3 Interventional Results available

Sulopenem Versus Ertapenem for Complicated Intra-abdominal Infection (cIAI)

NCT03358576
View directory record Official record
Conditions
Intra Abdominal Infections
Interventions
Ertapenem, Sulopenem-Etzadroxil/Probenecid, Ciprofloxacin, Metronidazole, Amoxicillin-Clavulanate, Sulopenem
Drug
Lead sponsor
Iterum Therapeutics, International Limited
Industry
Eligibility
18 Years and older
Enrollment
674 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
12
States / cities
Chula Vista, California • Torrance, California • Idaho Falls, Idaho + 8 more
Source: ClinicalTrials.gov public record
Updated Nov 30, 2020 · Synced Sep 12, 2026, 2:45 PM EDT
Completed Not applicable Interventional Results available

INSPIRE Trial for Abdominal Infections

NCT05423743
View directory record Official record
Conditions
Abdominal (ABD) Infection
Interventions
Arm 1: Routine Care, Arm 2: INSPIRE Stewardship Bundle for Abdominal Infection
Other
Lead sponsor
Harvard Pilgrim Health Care
Other
Eligibility
18 Years and older
Enrollment
198,480 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
101
States / cities
Riverside, California • San Jose, California • Thousand Oaks, California + 79 more
Source: ClinicalTrials.gov public record
Updated Aug 14, 2025 · Synced Sep 12, 2026, 2:45 PM EDT
Completed Phase 3 Interventional Results available

A Study to Determine the Efficacy, Safety and Tolerability of Aztreonam-Avibactam (ATM-AVI) ± Metronidazole (MTZ) Versus Meropenem (MER) ± Colistin (COL) for the Treatment of Serious Infections Due to Gram Negative Bacteria.

NCT03329092
View directory record Official record
Conditions
Complicated Intra-abdominal Infection, Hosptial Acquired Pneumonia, Ventilator Associated Pneumonia
Interventions
ATM-AVI, MTZ, MER, COL
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older
Enrollment
422 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2023
U.S. locations
5
States / cities
Tucson, Arizona • Torrance, California • Springfield, Illinois
Source: ClinicalTrials.gov public record
Updated Dec 9, 2024 · Synced Sep 12, 2026, 2:45 PM EDT
Completed Phase 2 Interventional Results available

Prospective Multicenter Doubleblind Randomized Study of NXL104/Ceftazidime + Metronidazole vs. Meropenem in Treatment of Complicated Intra-abdominal Infections

NCT00752219
View directory record Official record
Conditions
Complicated Intra-abdominal Infections
Interventions
ceftazidime/NXL104 + metronidazole, meropenem
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 65 Years
Enrollment
204 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009
U.S. locations
9
States / cities
Los Angeles, California • Palm Springs, California • Detroit, Michigan + 5 more
Source: ClinicalTrials.gov public record
Updated Jul 2, 2018 · Synced Sep 12, 2026, 2:45 PM EDT
Completed Phase 3 Interventional Results available

Compare Ceftazidime-Avibactam + Metronidazole Versus Meropenem for Hospitalized Adults With Complicated Intra-Abdominal Infections

NCT01499290
View directory record Official record
Conditions
Complicated Intra-Abdominal Infection
Interventions
CAZ-AVI, Metronidazole, Meropenem
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 90 Years
Enrollment
493 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
4
States / cities
Chula Vista, California • San Diego, California • St Louis, Missouri + 1 more
Source: ClinicalTrials.gov public record
Updated Sep 5, 2017 · Synced Sep 12, 2026, 2:45 PM EDT
Completed No phase listed Observational

ABTHERA ADVANCE™ Use Without Wittman Patch

NCT04986943
View directory record Official record
Conditions
Necrotizing Pancreatitis
Interventions
Using ABTHERA Advance without a Wittmann Patch
Device
Lead sponsor
Wake Forest University Health Sciences
Other
Eligibility
22 Years and older
Enrollment
3 participants
Timeline
2020 – 2023
U.S. locations
1
States / cities
Charlotte, North Carolina
Source: ClinicalTrials.gov public record
Updated Aug 30, 2023 · Synced Sep 12, 2026, 2:45 PM EDT
Withdrawn No phase listed Observational

Collective Accuryn Physiologic Signals and Signatures

NCT03817281
View directory record Official record
Conditions
Critical Illness, Acute Kidney Injury, Sepsis, Septic Shock, Abdominal Compartment Syndrome
Interventions
Accuryn Monitoring System
Device
Lead sponsor
Potrero Medical
Industry
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Jan 12, 2021 · Synced Sep 12, 2026, 2:45 PM EDT
Completed Phase 2 Interventional Results available

Study Evaluating the Pharmacokinetics (PK), Safety, and Tolerability of Tigecycline in Patients 8 to 11 Years of Age

NCT00488345
View directory record Official record
Conditions
Bacterial Infections, Intra-Abdominal Infection, Pneumonia, Bacterial, Skin Diseases, Bacterial, Skin Diseases, Infectious
Interventions
Tygacil
Drug
Lead sponsor
Wyeth is now a wholly owned subsidiary of Pfizer
Industry
Eligibility
8 Years to 11 Years
Enrollment
59 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2009
U.S. locations
18
States / cities
Long Beach, California • Oakland, California • Orange, California + 15 more
Source: ClinicalTrials.gov public record
Updated Oct 23, 2012 · Synced Sep 12, 2026, 2:45 PM EDT
Completed Phase 1Phase 2 Interventional Results available

Pharmacokinetic (PK) and Safety Study of Meropenem in Young Infants With Intra-abdominal Infections

NCT00621192
View directory record Official record
Conditions
Necrotizing Enterocolitis, Intra-abdominal Infection
Interventions
meropenem
Drug
Lead sponsor
The Emmes Company, LLC
Industry
Eligibility
Up to 90 Days
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
26
States / cities
Birmingham, Alabama • Oakland, California • Orange, California + 21 more
Source: ClinicalTrials.gov public record
Updated Apr 24, 2023 · Synced Sep 12, 2026, 2:45 PM EDT
Recruiting Phase 2 Interventional

Study of 2 Medicines (Aztreonam and Avibactam) Compared to Best Available Therapy for Serious Gram-negative Infections

NCT05639647
View directory record Official record
Conditions
Gram-negative Bacterial Infections
Interventions
ATM-AVI, BAT
Drug
Lead sponsor
Pfizer
Industry
Eligibility
9 Months to 17 Years
Enrollment
48 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
3
States / cities
San Diego, California • New York, New York
Source: ClinicalTrials.gov public record
Updated Jun 30, 2026 · Synced Sep 12, 2026, 2:45 PM EDT
Completed Phase 2 Interventional Results available

Evaluation of Safety,Pharmacokinetics and Efficacy of CAZ-AVI With Metronidazole in Children Aged 3 Months to 18 Years Old With Complicated Intra-abdominal Infections (cIAIs).

NCT02475733
View directory record Official record
Conditions
Complicated Intra-abdominal Infections
Interventions
Ceftazidime -avibactam, Meropenem, Metronidazole
Drug
Lead sponsor
Pfizer
Industry
Eligibility
3 Months to 17 Years
Enrollment
83 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
4
States / cities
Orange, California • San Diego, California • Toledo, Ohio + 1 more
Source: ClinicalTrials.gov public record
Updated Aug 8, 2018 · Synced Sep 12, 2026, 2:45 PM EDT
Terminated Phase 2 Interventional Results available

LYS228 PK, Clinical Response, Safety and Tolerability in Patients With Complicated Intra-abdominal Infection (cIAI)

NCT03354754
View directory record Official record
Conditions
Intra-abdominal Infections
Interventions
LYS228, Standard of care therapy
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years to 65 Years
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018
U.S. locations
1
States / cities
Somers Point, New Jersey
Source: ClinicalTrials.gov public record
Updated Oct 10, 2021 · Synced Sep 12, 2026, 2:45 PM EDT
Completed Phase 2Phase 3 Interventional Results available

Antibiotic Safety (SCAMP)

NCT01994993
View directory record Official record
Conditions
Complicated Intra Abdominal Infections
Interventions
ampicillin and metronidazole and gentamicin, ampicillin and gentamicin and clindamycin, gentamicin and Piperacillin- tazobactam, standard of care antibiotics and metronidazole, metronidazole, clindamycin, or piperacillin-tazobactam
Drug
Lead sponsor
Michael Cohen-Wolkowiez
Other
Eligibility
Up to 120 Days
Enrollment
260 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2017
U.S. locations
45
States / cities
Birmingham, Alabama • Little Rock, Arkansas • Loma Linda, California + 35 more
Source: ClinicalTrials.gov public record
Updated May 29, 2019 · Synced Sep 12, 2026, 2:45 PM EDT
Completed Phase 3 Interventional Results available

Study Comparing the Safety and Efficacy of Intravenous CXA-201 and Intravenous Meropenem in Complicated Intraabdominal Infections

NCT01445678
View directory record Official record
Conditions
Complicated Intra-abdominal Infection
Interventions
CXA-201 and metronidazole, Meropenem
Drug
Lead sponsor
Cubist Pharmaceuticals LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
Industry
Eligibility
18 Years and older
Enrollment
494 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2013
U.S. locations
4
States / cities
Springfield, Illinois • Boston, Massachusetts • Robbinsdale, Minnesota + 1 more
Source: ClinicalTrials.gov public record
Updated Nov 15, 2018 · Synced Sep 12, 2026, 2:45 PM EDT
Terminated Phase 2 Interventional Accepts healthy volunteers Results available

Antibiotic Irrigations for Intra-Abdominal Drains

NCT03476941
View directory record Official record
Conditions
Abdominal Abscess
Interventions
Gentamicin Sulfate Inj 20mg/2ml vial for injection, Clindamycin phosphate 6 mg/1ml for injection, Placebo
Drug · Other
Lead sponsor
University of Iowa
Other
Eligibility
18 Years to 80 Years
Enrollment
2 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2020
U.S. locations
1
States / cities
Iowa City, Iowa
Source: ClinicalTrials.gov public record
Updated Sep 2, 2026 · Synced Sep 12, 2026, 2:45 PM EDT
Completed Phase 3 Interventional Results available

Efficacy and Safety Study of Eravacycline Compared With Meropenem in Complicated Intra-abdominal Infections

NCT02784704
View directory record Official record
Conditions
Complicated Intra-abdominal Infections, Complicated Appendicitis
Interventions
Eravacycline, Meropenem, Placebo
Drug
Lead sponsor
Tetraphase Pharmaceuticals, Inc
Industry
Eligibility
18 Years and older
Enrollment
500 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
6
States / cities
Los Angeles, California • Indianapolis, Indiana • Las Vegas, Nevada + 3 more
Source: ClinicalTrials.gov public record
Updated Jan 5, 2022 · Synced Sep 12, 2026, 2:45 PM EDT
Completed No phase listed Observational

Persistent Inflammation, Immunosuppression and Catabolism Syndrome (PICS): A New Horizon for Surgical Critical Care and Induced Frailty

NCT02711709
View directory record Official record
Conditions
Sepsis
Interventions
Frailty Measurements, Modified Minnesota Leisure Time Activities, Computed tomography morphometrics, Mobility Monitors
Other
Lead sponsor
University of Florida
Other
Eligibility
18 Years and older
Enrollment
53 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2026
U.S. locations
1
States / cities
Gainesville, Florida
Source: ClinicalTrials.gov public record
Updated Apr 15, 2026 · Synced Sep 12, 2026, 2:45 PM EDT
Completed Phase 4 Interventional Results available

Study Comparing Tigecycline Versus Ceftriaxone Sodium Plus Metronidazole in Complicated Intra-abdominal Infection

NCT00195351
View directory record Official record
Conditions
Appendicitis, Cholecystitis, Cross Infection, Diverticulitis, Peritonitis
Interventions
tigecycline, ceftriaxone sodium + metronidazole
Drug
Lead sponsor
Wyeth is now a wholly owned subsidiary of Pfizer
Industry
Eligibility
18 Years and older
Enrollment
467 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2008
U.S. locations
46
States / cities
Mobile, Alabama • Laguna Hills, California • Los Angeles, California + 38 more
Source: ClinicalTrials.gov public record
Updated Feb 24, 2013 · Synced Sep 12, 2026, 2:45 PM EDT
Terminated Phase 3 Interventional Results available

A Safety and Tolerability Study of Doripenem Compared With Meropenem in Children Hospitalized With Complicated Intra-abdominal Infections

NCT01110382
View directory record Official record
Conditions
Abscess, Intra-Abdominal, Abdominal Abscess, Abdomen, Acute, Abdominal Pain, Appendicitis, Rupture, Infection, Intestinal Perforation, Peritonitis, Ileus
Interventions
Doripenem, Meropenem placebo, Meropenem, Doripenem placebo, Amoxicillin/clavulanate potassium
Drug
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
3 Months to 18 Years
Enrollment
41 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2013
U.S. locations
4
States / cities
San Diego, California • Washington D.C., District of Columbia • Cleveland, Ohio + 1 more
Source: ClinicalTrials.gov public record
Updated Jul 14, 2014 · Synced Sep 12, 2026, 2:45 PM EDT
Recruiting No phase listed Observational Accepts healthy volunteers

Diagnosis of Abdominal Pain Using RNA Levels: The NATURAL Study

NCT07579312
View directory record Official record
Conditions
Intra Abdominal Infections, Appendicitis Acute, Pyelonephritis, Diverticulitis, Epiploic Appendagitis
Interventions
TruNAV, an RNA-based blood test for host immune activation by infections
Diagnostic Test
Lead sponsor
True Bearing Diagnostics, Inc.
Industry
Eligibility
7 Years and older
Enrollment
1,000 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026 – 2027
U.S. locations
1
States / cities
Washington D.C., District of Columbia
Source: ClinicalTrials.gov public record
Updated May 11, 2026 · Synced Sep 12, 2026, 2:45 PM EDT